These results strengthen the view that A2AR agonists should counteract psychosis development in PD patients upon dopaminergic treatment by targeting A2AR–D2R and A2AR–D3R heteroreceptor complexes in the ventral striatum (Fuxe et al. 2010b). This evidence concerns the gene ADORA2A and psychotic disorder.